Why the study?
To describe considerations for surgical and transcatheter mitral valve replacement in the treatment of functional mitral valve regurgitation.
Transcatheter mitral valve replacement is an emerging technology that shows promising early feasibility results for patients with functional mitral regurgitation who are at high surgical risk.
Surgical mitral intervention remains viable for operable severe functional MR; leaves open the role of emerging transcatheter replacement pending trials.
Surgical mitral valve intervention for severe functional, or secondary mitral regurgitation is a viable option for patients deemed to be operative candidates and can be performed via traditional sternotomy or by minimally invasive techniques with similar outcomes. Transcatheter mitral valve replacement is an emerging technology with a potential role in the treatment of functional mitral valve regurgitation. A plethora of devices are currently in development and in various stages of clinical investigation. Operative approach to transcatheter mitral valve replacement varies from a percutaneous transseptal approach to a hybrid percutaneous/surgical apical approach. The Tendyne, Intrepid and Evoque systems show promising results from their early feasibility studies in treatment of patients with mitral regurgitation that were too high risk for surgery. In this review, we describe considerations for surgical and transcatheter mitral valve replacement for functional mitral valve regurgitation.
No takes yet. Share an insight, caveat, or question.
Scott et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: